Μετάβαση στο περιεχόμενο

Teva Scraps A Study In Cluster Headaches — And This Rival Benefits

dt005342Alder Biopharmaceuticals (ALDR) stock gapped up Friday after rival Teva Pharmaceutical (TEVA) scrapped a late-stage study of its anti-CGRP migraine prevention drug in chronic cluster headaches.

 

At the closing bell on the stock market today, Alder popped 6.7%, to 17.65. Shares of Teva dipped a fraction, to 23.76. Rival Eli Lilly (LLY) rose a fraction and Amgen (AMGN), which was the first to get a migraine prevention drug to market, dipped 0.4%.

Teva studied fremanezumab in chronic and episodic cluster headaches, as well as a long-term safety study. Researchers found fremanezumab is unlikely to work in chronic cluster headaches during the 12-week treatment period, and ended that study.

Fremanezumab belongs to a class called anti-CGRP drugs, which aim to block a specific peptide associated with migraines. It’s possible anti-CGRP drugs could have other uses, Teva spokesperson Tushar Shah said in a statement.

«While we are disappointed with this outcome, we remain optimistic that fremanezumab could have clinical benefits in additional conditions, beyond migraine, where calcitonin gene-related peptide plays a contributory role in their pathophysiology,» he said.

Other Anti-CGRP Drugs

Amgen and partner Novartis (NVS) grabbed approval in May for anti-CGRP drug Aimovig in migraine prevention. For the week ended June 8, Aimovig prescriptions grew 102% week over week to 2,129, RBC analyst Kennan MacKay said in a note.

Alder is testing its drug, eptinezumab, as a preventive treatment for episodic and chronic migraines. It also has a migraine prevention drug in preclinical studies. Lilly’s galcanezumab is under review in migraine prevention and is also being studied in cluster headaches.

Meanwhile, Biohaven Pharmaceutical (BHVN) has an anti-CGRP drug in development as an acute treatment for migraines. It’s also testing another anti-CGRP drug to treat and prevent migraines. Allergan (AGN), too, has an anti-CGRP in development as an acute treatment for migraines.

 

Πηγή: https://www.investors.com/

Thanasis Chalikias Προβολή όλων

A Product Manager with expertise in pharma marketing and sales operations

Σχολιάστε

Εισάγετε τα παρακάτω στοιχεία ή επιλέξτε ένα εικονίδιο για να συνδεθείτε:

Λογότυπο WordPress.com

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό WordPress.com. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Google+

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Google+. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Twitter

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Twitter. Αποσύνδεση /  Αλλαγή )

Φωτογραφία Facebook

Σχολιάζετε χρησιμοποιώντας τον λογαριασμό Facebook. Αποσύνδεση /  Αλλαγή )

Σύνδεση με %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Αρέσει σε %d bloggers: